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Abstract
Purpose To investigate whether narrow band imaging
(NBI)-assisted transurethral resection (TUR) (NBI-TUR)
has an impact on non-muscle invasive bladder cancer
(NMIBC) residual tumour rate compared to white light
(WL)-assisted TUR (WL-TUR).
Methods Patients with NMIBC treated with either NBI-
or WL-TUR were compared in a frequency-matched index-
control setting. During NBI-TUR, all suspicious lesions
identiﬁed by either WL or NBI were resected. Index
patients (NBI-TUR, n = 40) were prospectively recruited
and control patients (WL-TUR, n = 120) were retrospec-
tively collected, whilst being blinded for their ﬁrst follow-
up (fFU)-status. Non-radical TUR cases, patients without
evidence of urothelial carcinoma in the pathology speci-
men and those with isolated carcinoma in situ or muscle
invasive disease were excluded. Matching was based on the
risk of tumour recurrence deﬁned by (a) the EORTC risk
score for recurrence and (b) the administration or not of
one single chemotherapeutic intravesical instillation
immediately after TUR. All patients underwent routine
follow-up with WL cystoscopy supplemented with cytol-
ogy at 3 months or re-TUR in selected cases. The residual
tumour rates at fFU (RR-fFU) of patients with NMIBC
submitted to either NBI- or WL-TUR were compared.
Results Baseline patient and tumour characteristics were
comparable between groups. The RR-fFU for WL- and
NBI-TUR was 30.5% (36 out of 118 patients) and 15.0%
(6 out of 40 patients), respectively (OR: 2.7, one-sided 95%
CI: 1.2–6.1; P = 0.03).
Conclusion NBI-TUR decreases residual tumour rate
signiﬁcantly when compared to a matched cohort of
WL-TUR.
Keywords Cystoscopy  Narrow band imaging 
Recurrence  Transurethral resection  Urinary bladder
neoplasms
Introduction
One of the major challenges in the management of non-
muscle invasive bladder cancer (NMIBC) is to reduce the
high frequency of early recurrences, detected in up to
45% of the patients at ﬁrst follow-up (fFU) cystoscopy,
3 months following transurethral resection (TUR) [1].
These recurrences may be ‘‘true’’ recurrences due to
aggressive tumour biology or implantation of ﬂoating
cancer cells. However, it is believed that most of these
early ‘‘recurrences’’ in fact are overlooked or residual
tumours, which stresses the importance of TUR quality [1].
Although a re-TUR contributes to a more complete resec-
tion [2–5], it is an additional invasive procedure, increasing
the overall patient burden and healthcare costs. Therefore,
instead of repeating the standard procedure, improving the
technique itself represents a challenge.
Narrow band imaging (NBI) system (Olympus, Tokyo,
Japan) is a diagnostic modality recently added to the
urologist’s armamentarium. It is an optical tool, indepen-
dent of ﬂuorescent agents, aiming at improving the
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bandwidths of 415 and 540 nm, which correspond to blue
and green light, respectively. Due to the fact that these
wavelengths are speciﬁcally absorbed by haemoglobin, the
contrast between normal urothelium and vascular struc-
tures is enhanced. We have previously reported that NBI
cystoscopy improves the detection of NMIBC compared to
standard WL cystoscopy [6]. The aim of this study is to
investigate whether this improved detection rate during
NBI-assisted TUR (NBI-TUR) translates into a decrease in
NMIBC residual tumour rate compared to WL-TUR.
Materials and methods
Study design
The residual tumour rate at fFU (RR-fFU) of patients with
NMIBC submitted to either NBI- or WL-TUR in our centre
was compared in a frequency-matched index-control set-
ting. Index patients submitted to NBI-TUR were prospec-
tively recruited. Control patients submitted to WL-TUR
were retrospectively collected, whilst being blinded for
their fFU status. Matching was based on the risk of tumour
recurrence deﬁned by (a) the European Organization for
Research and Treatment of Cancer (EORTC) risk score for
recurrence [7] stratifying patients into three distinct groups
(low-, intermediate- and high risk) as proposed by the
European Association of Urology (EAU) working group
[8] and (b) the administration or not of one single che-
motherapeutic intravesical instillation immediately after
TUR. By combining these two criteria, six different
matching subgroups were generated.
All patients underwent routine follow-up with ﬂexible
WL cystoscopy supplemented by bladder-wash out cytol-
ogy at 3 months or re-TUR in selected cases. The indica-
tion for immediate and/or adjuvant instillations was based
on risk group criteria and not imposed by the study pro-
tocol. Histopathological staging and grading was based on
the TNM 2002 [9] and the WHO 1973 guidelines [10]. The
prospective part of this study (NBI-TUR group) was
approved by the local medical ethics committee.
Patient selection and procedures
From September 2007 to January 2010, consecutive
patients with a suspicion of primary or recurrent bladder
cancer based on cystoscopy or cytology ﬁndings were
prospectively enrolled and submitted to NBI-TUR. The
procedure has been previously described by Cauberg et al.
[6]. In brief, under anaesthesia, all patients underwent WL
cystoscopy followed by NBI cystoscopy. All tumours or
suspicious areas were mapped and subsequently resected or
biopsied under guidance of both techniques. Non-radical
TUR cases based on the surgeon’s intra-operative impres-
sion, patients without evidence of urothelial carcinoma in
the pathology specimen, as well as those with isolated
carcinoma in situ or muscle invasive disease were excluded
from the study.
To generate the WL control cohort, data of all patients
submitted to WL-TUR or biopsies for bladder cancer in our
centre from January 2000 to September 2007 were retro-
spectively evaluated. Eligible patients were ﬁltered out
using the aforementioned exclusion criteria and were
scored based on the matching criteria deﬁned above.
Finally, a random subset of patients was included: for each
matching group triple the number of NBI-patients in that
group, using nQuery Advisor 7.0.
All TURs performed in our centre (WL and NBI cohort)
are standardised: for all tumours a deep biopsy is taken and
sent to the pathologist in a separate container. Random cold
cup biopsies are only taken in case of positive (high grade)
urine cytology and negative cystoscopy. The quality of the
video systems used for both cohorts was comparable: NBI-
TUR was performed with 30 optics connected to an
Olympus Evis Exera II xenon light source and WL-TUR
was performed with Hopkins II 30 optics connected to a
Karl Storz Xenon 300 light source.
Details of the selection process are presented in Fig. 1.
Sample size analysis
Based on prior studies on residual tumour rate at re-TUR
following photodynamic diagnosis (PDD)-assisted TUR
[11] we considered an absolute difference of 20% in
RR-fFU between NBI-TUR and WL-TUR as clinically
relevant. Taking into account that non-radical TURs were
to be excluded from this study, we estimated an RR-fFU
of 30% for the WL-TUR and an RR-fFU of 10% for the
NBI-TUR cohort. Using a one-sided continuity corrected
two sample Chi-square test and setting the probability of
type I error (a) at 0.05 and type II error (b) at 0.20
(desired power 80%), the sample sizes of the index and
the control groups with a ratio 1:3 were calculated to be
40 and 120 for NBI and WL, respectively (total sample
size n = 160). We chose for a 1:3 ratio in order to
increase the power of the study. We opted for a one-sided
test, instead of the more common two-sided approach,
because NBI is intended to be used as an add-on to WL,
rather than a replacement. In this study, NBI-TUR indeed
consisted of resection under guidance of both WL and
NBI, and therefore, this procedure can only result in
either equal or improved residual tumour rates, i.e. the
alternative hypothesis has only one direction [12]. Sample
size calculation was performed with the use of nQuery
Advisor 7.0.
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For each patient the results of the fFU were recorded. If
this consisted of cystoscopy plus cytology 3 months after
the TUR, written reports and recorded still images of sus-
picious lesions were available. If a second TUR was per-
formed to conﬁrm pathological stage after the initial TUR
and before the fFU cystoscopy at 3 months, the results of
this procedure were used as fFU data. Since virtually all
tumours identiﬁed at re-TUR and most tumours identiﬁed
at 3-month cystoscopy in fact are residual/overlooked
tumours rather than true recurrences, we present the ﬁnd-
ings of fFU as residual tumours.
Since frequency-matching design does not require a
matched data analysis [13], baseline categorical variables
as well as the main variable of interest (residual tumour at
fFU in the two cohorts) and baseline continuous variables
were analysed using Chi-square test, Fisher-exact test and
independent samples t test, respectively. Complementary,
unconditional logistic regression analysis was performed to
test the effect of intervention type (WL- or NBI-TUR) on
the residual tumour rate at fFU, after adjusting for the
matching variable to avoid odds ratio (OR) and its one-
sided 95% conﬁdence interval (CI) being biased by the
procedure of frequency matching [13].
Statistical analysis was performed using the Statistical
Package for Social Sciences, version 16.0 (SPSS, Chicago,
Ill., USA) and P\0.05 was considered statistically
signiﬁcant.
Results
All baseline characteristics were comparable between
groups (Table 1).
For the WL cohort, the fFU data were obtained by
cystoscopy and cytology in 97 patients (80.8%), by re-TUR
in 17 (15.9%) and in two (1.7%) patients a cystectomy was
Consecutive patients  18 years 
scheduled for TUR or bladder 
biopsies  
(Jan 2000 – Sep 2007) 
     N = 440 
Exclusion 
 - Muscle-invasive tumour N = 77 
 - Non radical TUR    N = 21 
- Isolated CIS    N = 18 
-  No  UC    N  =  77 
Included patients 
N = 187 
Consecutive patients  18 years 
scheduled for NBI-assisted TUR or 
bladder biopsies  
(Sep 2007 – Jan 2010) 
N = 73 
Included patients 
N = 40 
Exclusion 
 - Muscle-invasive tumour N = 14 
 - Non radical TUR    N = 6 
- Isolated CIS      N = 8 
-  No  UC    N  =  5 
Evaluated patients (random subset) 
N = 120 
Eligible patients 
N = 380 
Exclusion 
 - PDD-assisted TUR  N = 16 
 - evaluated for NBI group N = 41 
- participating in EOquin     N = 3 
     marker lesion study      
Eligible patients 
N = 73 
Evaluated patients  
N = 40 
Analysis set 
   N  =  118 
Analysis set 
N = 40 
Exclusion 
- fFU data missing       N = 2 
Fig. 1 Flow chart of patient
selection. TUR transurethral
resection, NBI Narrow band
imaging, PDD Photodynamic
diagnosis, CIS Carcinoma
in situ, UC Urothelial
carcinoma, fFU ﬁrst follow-up
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recurrent T1G3 disease. fFU data were missing from two
patients (1.7%): one patient died within 3 months after the
TUR due to non-urological cause and the other patient
declined follow-up based on her age (84 yr). For the NBI
cohort, cystoscopy plus cytology was performed in 27
patients (67.5%) and re-TUR in 13 patients (32.5%).
Residual tumour was detected in 36 out of 118 patients
(30.5%) treated by WL-TUR and 6 out of 40 patients
(15.0%) treated by NBI-TUR, thus an absolute difference
in RR-fFU of 15.5% in favour of NBI-TUR (P = 0.04).
The above result was veriﬁed in a logistic regression model
including matching variable as a covariate, showing that
the probability of recurrence at fFU is signiﬁcantly higher
in patients previously submitted to WL-TUR (OR 2.7,
one-sided 95% CI 1.2–6.1, P = 0.03). Pathology results of
the recurrences are displayed in Table 2.
Discussion
This is the ﬁrst report on the impact of NBI-TUR on
residual tumour rate. It has been previously shown that NBI
cystoscopy signiﬁcantly improves NMIBC detection since
additional tumours missed during WL cystoscopy were
seen using NBI technology, in 22–56% of the patients [6,
14–17]. Consequently, it is expected that NBI improves
TUR quality by contributing to resection completeness,
thereby reducing the residual tumour rate. In the current
study we provide evidence to support this concept, showing
Table 1 Baseline
characteristics
a independent t test
* Chi-square
NBI Narrow band imaging,
WL white light, CIS Carcinoma
in situ, MMC Mitomycin C,




2 (df)o rF( df) P value
Number of patients 40 120 – –
Sex (%)
Male 30 (75.0) 86 (71.7) 0.17 (1) 0.68*
Female 10 (25.0) 34 (28.3)
Age, mean (SD) yrs 67.9 (13.2) 67.8 (9.6) 8.62 (158) 0.94
a
Number of tumours (%)
Unifocal 19 (47.5) 66 (55.0) 0.68 (1) 0.41*
Multifocal 21 (52.5) 54 (45.0)
Prior recurrence rate (%)
Primary 28 (70.0) 70 (58.3) 1.72 (1) 0.19*
Recurrence 12 (30.0) 50 (41.7)
Stage (%)
Ta 28 (70.0) 91 (75.8) 0.54 (1) 0.46*
T1 12 (30.0) 29 (24.2)
Grade (%)
1 3 (7.5) 11 (9.2) 2.45 (2) 0.29*
2 15 (37.5) 60 (50.0)
3 22 (55.0) 49 (40.8)
Concomitant CIS (%) 4 (10.0) 9 (7.5) 0.25 (1) 0.62*
EORTC risk group (%)
Low 2 (5.0) 6 (5.0) 0.00 (2) 1.00*
Intermediate 33 (82.5) 99 (82.5)
High 5 (12.5) 15 (12.5)
Immediate instillation (%) 17 (42.5) 51 (42.5) 0.00 (1) 1.00*
Adjuvant instillations (%)
None 23 (57.5) 69 (57.5) 0.32 (2) 0.85*
Chemotherapy 6 (15.0) 22 (18.3)
MMC 2 (5.0) 11 (9.2)
MMC ? hyperthermia 4 (10.0) 2 (1.7)
EOquin 0 (0.0) 3 (2.5)
KLH 0 (0.0) 5 (4.2)
Epirubicin 0 (0.0) 1 (0.8)
Immunotherapy (BCG) 11 (27.5) 29 (24.2)
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123that the residual tumour rate after NBI-TUR is signiﬁcantly
lower compared to standard WL-TUR (15 vs. 30.5%,
respectively). Based on the logistic regression analysis, we
can state that the odds for detecting a tumour up to
3 months after WL-TUR is 2.7 times higher than after
NBI-TUR.
Potential limitations of our study are related to its
design, namely the retrospective collection of the control
group. First, it may be speculated that retrospectively col-
lected data including baseline characteristics or informa-
tion on TUR radicality was more difﬁcult to retrieve.
Nevertheless, there were no missing data on baseline
characteristics, which underlines the documentation qual-
ity. In only two patients (1.7%) data on fFU was lacking,
due to non-speciﬁc circumstances. For all other WL-cohort
patients, results of fFU cystoscopy were well documented
with an electronic report supplemented by bladder diagram,
recorded still images of abnormal looking urothelium and
bladder-wash out cytology. In cases with re-TUR, the
surgical as well as the ﬁnal pathological report were avail-
able electronically for all patients. Second, the WL-TUR
cohort was treated in an earlier era than the NBI-patients,
which may have inﬂuenced the outcome. However, the
treatment strategy has not been altered over these years: the
ﬁrst EAU guidelines on bladder cancer already advocated
a complete TUR, supplemented by the administration of
one single chemotherapeutic intravesical instillation
immediately after TUR, and adjuvant instillations in the
intermediate- and high risk group [18]. This is illustrated
by the similar number of patients with adjuvant courses
of intravesical therapy. In addition, the type of adjuvant
therapy was not signiﬁcantly different for the two inter-
vention groups (Table 1). Third, despite the fact that
re-TUR is the best proof of absence of residual tumour, a
re-TUR was not incorporated as a standard procedure in the
study protocol due to the partly retrospective design of the
study. Thus, most fFU data were based on outpatient
ﬂexible cystoscopy ﬁndings. Nevertheless, almost 33% of
patients in the NBI group and 16% in the WL group had a
re-TUR as part of routine management. It has to be noted
that in all these patients, re-TUR was performed to ensure
correct staging rather than due to doubt on radicality of the
ﬁrst TUR (which was an exclusion criterion). The differ-
ence in re-TUR ratios between the two groups may be
explained by the relatively higher number of pT1 and/or
grade 3 tumours in the NBI group (though not statistically
signiﬁcant), necessitating conﬁrmation of non-muscle
invasive disease.
To compare the effect of two interventions, it is crucial
that groups are identical on potential confounders. In this
study, we generated two comparable intervention groups
by frequency matching based on the EORTC risk criteria
and the single intravesical chemotherapy instillation status
immediately after TUR. These two factors are considered
the most important determinants of future bladder cancer
recurrence [19, 20].
Table 2 Pathology results of
residual tumours
* Fisher-exact test
NBI Narrow band imaging,
WL white light
NBI WL P value
Patients with residual tumour (%) 6 (15.0) 36 (30.5) 0.04*
Stage (%)
Ta 3 (50.0) 19 (52.8) –
T1 2 (33.3) 5 (13.9)
T2 1 (16.7) 1 (2.8)
Tis only 0 (0.0) 4 (11.1)
Unknown 0 (0.0) 7 (19.4)
Laser treatment – 4
No pathology obtained because of comorbidity – 2
Biopsy of insufﬁcient quality for staging – 1
Grade (%)
1 1 (16.7) 2 (5.6) –
2 0 (0.0) 13 (36.1)
3 4 (66.7) 15 (41.7)
Unknown 1 (16.7) 6 (16.7)
Laser treatment – 4
No pathology obtained because of comorbidity – 2
Biopsy of insufﬁcient quality for grading 1 –
Residual tumour upstaged/upgraded if compared to initial tumour(s) 2 (33.3) 6 (16.7) –
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123Attempting to decrease the well-known high number of
early recurrences in NMIBC is of utmost importance
because these recurrences necessitate meticulous follow-
up with cystoscopy plus cytology and adjuvant courses of
intravesical therapy in selected cases, all of which result in
high patients’ burden and increased costs. In fact, it has
been estimated that bladder cancer is one of the most
expensive cancers of today’s medical practice, mainly due
to the lifelong need for follow-up and repeated treatments
[21]. Many studies have already proven that PDD is
effective in reducing the early recurrence rate [22–25].
However, there are some drawbacks of PDD that have
restricted a widespread use. Since NBI does not require an
intravesical ﬂuorescent it has advantages over PDD, pro-
vided that the system proves to be equally effective.
Theoretically, the expenditures probably will be lower,
there is no risk of side-effects and the technique is
immediately applicable without necessitating a special
patient preparation.
Of course additional randomized and/or multicentre
trials are warranted to conﬁrm these ﬁrst promising results.
However, despite the lower level of evidence that the
current study provides, it is important to have this evidence
before investing time and money in constructing a ran-
domised controlled trial. Partly triggered by the results of
this trial, the clinical research ofﬁce of the endourological
society is currently doing a multicentre, international,
randomised trial on the effect of NBI-assisted TUR on
recurrence rates [26]. In addition, future studies have to
investigate whether this improved outcome at 3 months
will sustain at longer follow-up. Another interesting
objective for future research could be to compare the effect
of standard WL-TUR followed by adjuvant intravesical
therapy with NBI-TUR without this adjuvant therapy. If the
NBI-TUR can inﬂuence recurrence rate to such an extent
that these intravesical therapies become redundant, this
would have a major impact on healthcare, both for the
patients (increased quality of life) as well as the economics
(less healthcare costs).
Conclusions
This is the ﬁrst study demonstrating that NBI-TUR for
NMIBC decreases residual tumour rate signiﬁcantly when
compared to a matched cohort of WL-TUR.
Residual tumour rate was 30.5% in patients treated by
WL-TUR and 15.0% in patients treated by NBI-TUR, thus
a statistically signiﬁcant absolute difference of 15.5% in
favour of NBI-TUR.
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